MX2020008610A - Agente terapeutico para carcinoma hepatocelular. - Google Patents

Agente terapeutico para carcinoma hepatocelular.

Info

Publication number
MX2020008610A
MX2020008610A MX2020008610A MX2020008610A MX2020008610A MX 2020008610 A MX2020008610 A MX 2020008610A MX 2020008610 A MX2020008610 A MX 2020008610A MX 2020008610 A MX2020008610 A MX 2020008610A MX 2020008610 A MX2020008610 A MX 2020008610A
Authority
MX
Mexico
Prior art keywords
therapeutic agent
hepatocellular carcinoma
methoxyethoxy
benzamide
piperidin
Prior art date
Application number
MX2020008610A
Other languages
English (en)
Inventor
Saori MIYANO
Atsumi Yamaguchi
Hajime Shimizu
Satoshi Goda
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2020008610A publication Critical patent/MX2020008610A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe un agente terapéutico para carcinoma hepatocelular que comprende 5-((2-(4-(1-(2-hidroxietil)piperidin-4-il)benzamida) piridin-4-il)oxi)-6-(2-metoxietoxi)-N-metil-1H-indol-1-carboxamid a o una sal farmacológicamente aceptable de ésta.
MX2020008610A 2018-03-28 2019-03-26 Agente terapeutico para carcinoma hepatocelular. MX2020008610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018061447 2018-03-28
PCT/JP2019/012971 WO2019189241A1 (ja) 2018-03-28 2019-03-26 肝細胞癌治療剤

Publications (1)

Publication Number Publication Date
MX2020008610A true MX2020008610A (es) 2020-09-21

Family

ID=68060624

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008610A MX2020008610A (es) 2018-03-28 2019-03-26 Agente terapeutico para carcinoma hepatocelular.

Country Status (12)

Country Link
US (1) US11219619B2 (es)
EP (1) EP3777860A4 (es)
JP (1) JPWO2019189241A1 (es)
KR (1) KR20200135945A (es)
CN (1) CN111712245A (es)
AU (1) AU2019241625A1 (es)
BR (1) BR112020017922A2 (es)
CA (1) CA3091153A1 (es)
IL (1) IL276935A (es)
MX (1) MX2020008610A (es)
SG (1) SG11202007591RA (es)
WO (1) WO2019189241A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3180128A1 (en) 2020-04-17 2021-10-21 Eisai R&D Management Co., Ltd. Breast cancer therapeutic agent
JPWO2022025150A1 (es) 2020-07-31 2022-02-03
CN116390757A (zh) 2020-10-28 2023-07-04 卫材R&D管理有限公司 用于***的药物组合物

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
IL155447A0 (en) 2000-10-20 2003-11-23 Eisai Co Ltd Nitrogenous aromatic ring compounds
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
NZ538617A (en) 2002-08-30 2005-12-23 Eisai Co Ltd Azaarene derivatives
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2006522756A (ja) 2003-04-10 2006-10-05 エフ．ホフマン−ラ　ロシュ　アーゲー ピリミド化合物
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
SMP200800041B (it) 2005-12-21 2009-07-14 Novartis Ag Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008078100A2 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
WO2008078091A1 (en) 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CA2690355A1 (en) 2007-06-25 2008-12-31 Qinetiq Limited Preconcentrator device incorporating a polymer of intrinsic microporosity
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
CL2008003675A1 (es) 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
CA2728063A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
US8263610B2 (en) 2008-12-30 2012-09-11 Arqule, Inc. Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds
JP5739820B2 (ja) 2008-12-30 2015-06-24 アークル インコーポレイテッド 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミン化合物
AU2009335019A1 (en) 2008-12-30 2011-08-18 Arqule, Inc. Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
KR101529767B1 (ko) 2009-08-07 2015-06-17 추가이 세이야쿠 가부시키가이샤 아미노피라졸 유도체
WO2011051425A1 (en) 2009-10-30 2011-05-05 Novartis Ag N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
HUE041987T2 (hu) 2011-07-19 2019-06-28 Merck Sharp & Dohme 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
EP2657233B1 (en) 2012-01-19 2014-08-27 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
IN2014DN05869A (es) 2012-01-31 2015-05-22 Novartis Ag
PT2821402T (pt) 2012-02-28 2019-10-02 Kotobuki Pharmaceutical Co Ltd Composto aromático heterocíclico que contém nitrogénio
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
AR091424A1 (es) 2012-06-13 2015-02-04 Incyte Corp Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr)
WO2014007369A1 (ja) 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Ｆｇｆｒ２融合遺伝子
EP2872491B1 (en) 2012-07-11 2021-05-05 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
JP6117222B2 (ja) 2012-09-27 2017-04-19 中外製薬株式会社 Ｆｇｆｒ３融合遺伝子およびそれを標的とする医薬
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
WO2014145751A2 (en) 2013-03-15 2014-09-18 The Translational Genomics Research Institute Targeted therapies for cancer
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
MX2017009892A (es) 2015-03-25 2017-11-15 Nat Cancer Ct Agente terapeutico contra el colangiocarcinoma.
CA3001969C (en) 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer

Also Published As

Publication number Publication date
RU2020127993A3 (es) 2022-04-28
EP3777860A1 (en) 2021-02-17
JPWO2019189241A1 (ja) 2021-03-18
WO2019189241A1 (ja) 2019-10-03
IL276935A (en) 2020-10-29
SG11202007591RA (en) 2020-09-29
RU2020127993A (ru) 2022-04-28
KR20200135945A (ko) 2020-12-04
CN111712245A (zh) 2020-09-25
AU2019241625A1 (en) 2020-09-03
CA3091153A1 (en) 2019-10-03
EP3777860A4 (en) 2021-12-15
US20200375970A1 (en) 2020-12-03
BR112020017922A2 (pt) 2020-12-22
US11219619B2 (en) 2022-01-11

Similar Documents

Publication Publication Date Title
MX2017009892A (es) Agente terapeutico contra el colangiocarcinoma.
MX2023000085A (es) Compuestos antiproliferativos y metodos para utilizarlos.
MX2020008610A (es) Agente terapeutico para carcinoma hepatocelular.
NZ595553A (en) VINYL INDAZOLYL COMPOUND; (E)-2-(4-(2-(5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazol-3-yl)vinyl)-1H-pyrazol-1-yl)ethanol
MX2018006329A (es) Agente terapeutico para cancer de mama.
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
MX2021006091A (es) Sales y formas solidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi) -1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que comprenden y metodos para utilizar las mismas.
UA111725C2 (uk) Кристалічний (r)-(e)-2-(4-(2-(5-(1-(3,5-дихлорпіридин-4-іл)етоксі)-1h-індазол-3-іл)вініл)-1h-піразол-1-іл)етанол
NZ598582A (en) Novel phenol derivative having uricsuric effect
MX2022000249A (es) Formas cristalinas de un inhibidor de magl.
MX2016009011A (es) Compuestos de indazol como inhibidores de cinasa-4 asociada al receptor de interleucina-1 (irak4).
PH12017501007A1 (en) Compositions comprising 2-((1-(2 - (4-fluorophenyl) -2- oxoethyl) piperidin-4-yl) methyl) isoindolin-1-one for treating schizophrenia
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
WO2014100719A3 (en) Teatrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof
DK2882442T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidin-2,6-dion
MA38078B1 (fr) Dérivé de pyridine
MX2016005680A (es) Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea.
MX2016012687A (es) Derivados de 2,4-tiazolidindiona en el tratamiento de trastornos del sistema nervioso central.
MX2019011183A (es) Nuevo uso terapeutico de h3-ligandos.
MX2022012934A (es) Agente terapeutico para cancer de mama.
IL292667A (en) Combination of t-cell therapy and (s)-3-[4-(4-morpholine-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2- discussion
PH12018502446A1 (en) (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders
MX2020002083A (es) Composicion farmaceutica que comprende un inhibidor tirosina cinasa selectivo para receptores del factor de crecimiento de fibroblastos (fgfr).
UA98158U (uk) Фторфенілпохідні 1,2,4-триазол-3-тіолів, що проявляють аналгетичну активність
MX354518B (es) Derivado de 6-oxo-1, 6-dihidro-piridazina para uso en el tratamiento de carcinoma hepatocelular (hcc).